Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for breath-holding spells in children
IRCT20200203046350N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risperidone in Breath-holding spell (BHS), sponsored by Tehran University of Medical Sciences. Primary endpoints: Number of breath-holding attacks and Breath-holding grade. Started Jul 2020; status: completed.
02
Drugs
risperidone
03
Conditions
Breath-holding spell (BHS)
Beyond the preview
Go deeper on IRCT20200203046350N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200203046350N1.